Lead Product(s) : Golexanolone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study results show that treatment with Golexanolone (GR3027) for 7 days significantly reduced fatigue in test group compared to the control group (p<0.05). Further analysis shows that treatment also improved other CNS symptoms.
Product Name : GR3027
Product Type : Steroid
Upfront Cash : Inapplicable
September 28, 2022
Lead Product(s) : Golexanolone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Golexanolone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results from previous clinical and pre-clinical studies strongly indicate that GR3027 (golexanolone) is able to counteract such inappropriate suppression of brain activity.
Product Name : GR3027
Product Type : Steroid
Upfront Cash : Inapplicable
September 14, 2022
Lead Product(s) : Golexanolone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Golexanolone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Golexanolone, a novel drug candidate that counter acts the effect of allopregnanolone on GABAA receptors, thereby restoring normal nerve signalling in the brain.
Product Name : GR3027
Product Type : Steroid
Upfront Cash : Inapplicable
March 11, 2021
Lead Product(s) : Golexanolone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Golexanolone
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Analyses of data for additional efficacy endpoints reveal that treatment with the golexanolone exerts a significant effect on brain signaling with a positive effect on excessive daytime sleepiness.
Product Name : GR3027
Product Type : Steroid
Upfront Cash : Inapplicable
August 05, 2020
Lead Product(s) : Golexanolone
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Golexanolone
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results demonstrate a positive safety and tolerability profile; however, no indications of clinical effects could be observed.
Product Name : GR3027
Product Type : Steroid
Upfront Cash : Inapplicable
March 04, 2020
Lead Product(s) : Golexanolone
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Golexanolone
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Umecrine Cognition will present the results from its recently conducted clinical phase 2a study of the drug candidate golexanonole, that is in clinical development for hepatic encephalopathy.
Product Name : GR3027
Product Type : Steroid
Upfront Cash : Inapplicable
February 09, 2020
Lead Product(s) : Golexanolone
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable